<div id="readability-page-1"><p>Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Stryker Corporation <span>NYSE: SYK<span></span></span>. In a filing disclosed on December 19th, the Representative disclosed that they had sold between $15,001 and $50,000 in Stryker stock on November 20th. The trade occurred in the Representative's &#34;STATE STREET BANK &amp; TRUST CO.&#34; account.</p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>Representative Thomas H. Kean, Jr. also recently made the following trade(s): </p><ul><li>Purchased $1,001 - $15,000 in shares of Texas Instruments <span>NASDAQ: TXN<span></span></span> on 11/26/2025. </li><li>Sold $15,001 - $50,000 in shares of Johnson &amp; Johnson <span>NYSE: JNJ<span></span></span> on 11/20/2025. </li><li>Sold $1,001 - $15,000 in shares of Fiserv <span>NASDAQ: FISV<span></span></span> on 10/31/2025. </li><li>Purchased $1,001 - $15,000 in shares of Intercontinental Exchange <span>NYSE: ICE<span></span></span> on 9/25/2025. </li></ul><h2>Stryker Price Performance</h2><p>Shares of NYSE SYK opened at $355.21 on Friday. The stock has a market cap of $135.84 billion, a price-to-earnings ratio of 46.68, a PEG ratio of 2.50 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The firm's 50-day simple moving average is $365.26 and its 200 day simple moving average is $377.51. </p><ul><li>Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?</li></ul><p>Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The firm's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS.  As a group, research analysts anticipate that  Stryker Corporation will post 13.47 earnings per share for the current fiscal year. </p><h2>Stryker Increases Dividend</h2><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, December 31st. This is an increase from Stryker's previous quarterly dividend of $0.84. Stryker's payout ratio is 44.15%. </p><h2>Insider Buying and Selling</h2><ul><li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li></ul><p>In other Stryker news, CFO Preston Wendell Wells sold 165 shares of the firm's stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares of the company's stock, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This trade represents a 40.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is owned by corporate insiders. </p><h2>Analyst Ratings Changes</h2><p>SYK has been the subject of a number of research reports. UBS Group  set a $408.00 price target on shares of Stryker in a research note on Monday, October 13th. Truist Financial lowered their price target on Stryker from $400.00 to $392.00 and set a &#34;hold&#34; rating on the stock in a research report on Thursday. Redburn Partners  set a $420.00 price target on Stryker in a research note on Thursday, September 18th. Rothschild &amp; Co Redburn began coverage on Stryker in a research report on Thursday, September 18th. They set a &#34;neutral&#34; rating and a $420.00 price objective on the stock. Finally, Royal Bank Of Canada  reissued an &#34;outperform&#34; rating and set a $435.00 price objective on shares of Stryker in a report on Friday, November 14th. Thirteen analysts have rated the stock with a Buy rating and six have issued  a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $431.84.</p><p><b>View Our Latest Stock Analysis on Stryker</b></p><h2>Hedge Funds Weigh In On Stryker</h2><p>A number of institutional investors and hedge funds have recently made changes to their positions in the business. Mid American Wealth Advisory Group Inc. bought a new stake in shares of  Stryker in the second quarter worth approximately $26,000.  Clayton Financial Group LLC bought a new position in shares of  Stryker in the third quarter worth about $26,000.  United Financial Planning Group LLC bought a new position in shares of  Stryker during the 3rd quarter valued at approximately $27,000.  Elevation Point Wealth Partners LLC purchased a new stake in  Stryker in the 2nd quarter worth approximately $28,000.  Finally, Sachetta LLC lifted its holdings in  Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 27 shares in the last quarter. Institutional investors own  77.09% of the company's stock. </p><h2>About Representative Kean</h2><p>Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.  Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election.  Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.</p><h2>About Stryker</h2> (Get Free Report)<p>Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.</p><h2>Read More</h2><ul><li>Five stocks we like better than Stryker</li><li>Transportation Stocks Investing</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>What is a Dividend King? </li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Stryker Right Now?</h2><p>Before you consider Stryker, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Rep. Thomas H. Kean, Jr. sold between $15,001 and $50,000 in Stryker Corporation stock on November 20th. The stock opened at $355.21, with a market cap of $135.84 billion. Stryker's recent earnings beat estimates, and the company increased its dividend. Analysts have mixed ratings, with price targets ranging from $392 to $435.</p>

Rep. Thomas H. Kean, Jr. Sells Stryker Corporation (NYSE:SYK) Stock